TY - JOUR
T1 - Transforming the evidence landscape in mental health with platform trials
AU - Gold, Stefan M.
AU - Mäntylä, Fanni Laura
AU - Donoghue, Kim
AU - Brasanac, Jelena
AU - Freitag, Michaela Maria
AU - König, Franz
AU - Posch, Martin
AU - Ramos-Quiroga, J. Antoni
AU - Benedetti, Francesco
AU - Köhler-Forsberg, Ole
AU - Grootendorst, Nina
AU - Hoogendijk, Witte
AU - Pariante, Carmine M.
AU - Katz, Elyse R.
AU - Webb, Steve
AU - Lennox, Belinda
AU - Furukawa, Toshi A.
AU - Otte, Christian
N1 - Publisher Copyright:
© Springer Nature America, Inc. 2025.
PY - 2025/3/10
Y1 - 2025/3/10
N2 - Clinical trials are at the core of evidence-based medicine, but many are underpowered and fail to inform clinical practice. In mental health, the number of regulatory drug approvals has consistently lagged behind other areas of medicine, the effects of established therapies may vary, and comparative effectiveness data for available treatments are scarce. Thus, there is an urgent need for more efficient, faster and more collaborative ways of generating evidence. Traditional approaches of ‘one treatment, one trial’ are slow, inefficient, and limit comparability across trials. In contrast, platform trials use a shared infrastructure for many treatments, shared control group(s) and a master protocol that allows treatments to be added over time and ineffective ones to be dropped early. Here we present examples of platform trials in mental health (M-PACT, EU-PEARLDIVER, PUMA and RESiLIENT) and discuss their potential to increase speed, reduce operational costs and participant burden, and improve statistical power and comparability.
AB - Clinical trials are at the core of evidence-based medicine, but many are underpowered and fail to inform clinical practice. In mental health, the number of regulatory drug approvals has consistently lagged behind other areas of medicine, the effects of established therapies may vary, and comparative effectiveness data for available treatments are scarce. Thus, there is an urgent need for more efficient, faster and more collaborative ways of generating evidence. Traditional approaches of ‘one treatment, one trial’ are slow, inefficient, and limit comparability across trials. In contrast, platform trials use a shared infrastructure for many treatments, shared control group(s) and a master protocol that allows treatments to be added over time and ineffective ones to be dropped early. Here we present examples of platform trials in mental health (M-PACT, EU-PEARLDIVER, PUMA and RESiLIENT) and discuss their potential to increase speed, reduce operational costs and participant burden, and improve statistical power and comparability.
UR - https://www.scopus.com/pages/publications/105000376950
U2 - 10.1038/s44220-025-00391-w
DO - 10.1038/s44220-025-00391-w
M3 - Article
AN - SCOPUS:105000376950
SN - 2731-6076
VL - 3
SP - 276
EP - 285
JO - Nature Mental Health
JF - Nature Mental Health
IS - 3
M1 - 562660
ER -
